Inhaled treprostinil for exercise-induced pulmonary hypertension
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of exercise-induced pulmonary hypertension, which means high blood pressure in the lungs only occurs during exercise.
- You should experience shortness of breath during physical activity.
- You must be able to perform an exercise test on a stationary bike or treadmill.
- If you could become pregnant, you must agree to use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medicine that may help people with lung scarring or connective tissue disease who have high blood pressure in the lungs only during exercise. It aims to improve their ability to be active and reduce symptoms.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This trial tests if special breathing exercises can help people with pulmonary hypertension. You may join if your condition is stable and you haven't smoked in the last 10 years.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.